Atea Pharmaceuticals (AVIR) Total Non-Current Liabilities (2019 - 2025)

Atea Pharmaceuticals' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $39.8 million for Q4 2025.

• In Q4 2025, Total Non-Current Liabilities rose 104.6% year-over-year to $39.8 million; the TTM figure through Dec 2025 stood at $39.8 million (up 104.6% YoY), while the FY2025 annual figure was $39.8 million, up 104.6% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $39.8 million, up from $20.4 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $273.7 million in Q2 2021, with the low at $14.6 million in Q1 2023.
• The 5-year median for Total Non-Current Liabilities is $26.2 million (2024), against an average of $52.1 million.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities plunged 89.81% in 2022, then jumped 193.33% in 2024.
• Atea Pharmaceuticals' Total Non-Current Liabilities stood at $56.9 million in 2021, then sank by 63.29% to $20.9 million in 2022, then surged by 62.91% to $34.0 million in 2023, then plunged by 42.84% to $19.4 million in 2024, then soared by 104.6% to $39.8 million in 2025.
• Business Quant data shows AVIR's Total Non-Current Liabilities at $39.8 million in Q4 2025, $20.4 million in Q3 2025, and $20.5 million in Q2 2025.